Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy
This study explores early breast cancer, focusing on triple-negative and high-risk luminal subtypes. It combines single-cell RNA sequencing and spatial imaging of tumor samples collected at different time points during treatment.
- Trial name
- ONSET (NCT07597642)
- Testing
- on treatment biopsy (after C1)
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
In this trial investigators propose to assess the dose dense, G-CSF supported sequential administration of 4 cycles of FEC followed by 4 cycles of docetaxel versus 6 cycles of docetaxel/cyclophosphamide as adjuvant chemotherapy…
- Trial name
- NCT01985724
- Testing
- Docetaxel, Epirubicin, Cyclophosphamide
- Where
- 10 sites in Greece
- Volunteers
- 650 people
- Sponsor
- Hellenic Oncology Research Group
Primary Breast Cancer, Her2 Non-overexpressing
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
The planned trial compares an anthracycline-free taxane based regimen versus a modern third generation (anthracycline/taxane-based) regimen in HER2/neu non-over expressing tumors.
- Trial name
- planB (NCT01049425)
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- Germany
- Volunteers
- 3,198 people
- Sponsor
- Women's Cancer Study Group GmbH
HER2-positive Breast Cancer
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis.
- Trial name
- TaxDHER2 (NCT06711068)
- Where
- China
- Volunteers
- 8,077 people
- Sponsor
- Shu Wang
Breast Cancer
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
It suggests in the Guideline that the postmenopausal women with breast cancer who have taken selective estrogen receptor modulators (SERMs) therapy for 2-3 years could benefit from changing endocrine therapy to aromatase…
- Trial name
- NCT02097459
- Testing
- Anastrozole, Tamoxifen, Toremifene
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking Union Medical College Hospital
HER2-positive Breast Cancer, Early-stage Breast Cancer
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and…
- Conditions
- HER2-positive Breast Cancer, Early-stage Breast Cancer, Breast Cancer, Breast Neoplasms
- Trial name
- NCT04109391
- Testing
- TX05 (trastuzumab), Herceptin (trastuzumab)
- Where
- 86 sites in Belarus, Chile and 8 more
- Volunteers
- 338 people
- Sponsor
- Tanvex BioPharma USA, Inc.
Breast Cancer, Breast Neoplasms
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
This is a phase III, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of pertuzumab biosimilar HLX11 vs.
- Conditions
- Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
- Trial name
- NCT05346224
- Testing
- HLX11, EU-Perjeta®
- Where
- 79 sites in China, Hungary and 2 more
- Volunteers
- 900 people
- Sponsor
- Shanghai Henlius Biotech
This Study Evaluates Interventions to Increase Surveillance Mammography Uptake for Early Breast Cancer Detection Among Singaporean Women in Real World
Community Study to Increase Mammogram Screening Among Overdue Women
Breast cancer is the most common cancer among women in Singapore, and regular mammogram screening can detect breast cancer early when treatment is more effective.
- Trial name
- IMPLEMENT (NCT07832396)
- Testing
- Evidence-based behavioural intervention
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
HR+/HER2-breast Cancer
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
This is a randomized, controlled, open, phase III trial of adjuvant intensive therapy for early breast cancer with HR+/ HER2-SNF4 based on SNF molecular typing.
- Trial name
- NCT05889871
- Testing
- Standard endocrine therapy plus Apatinib
- Volunteers
- 916 people
- Sponsor
- Fudan University
Breast Cancer
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-)…
- Trial name
- NCT06139107
- Testing
- Abemaciclib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mridula George, MD
HER2-positive Breast Cancer
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed…
- Trial name
- NCT04481932
- Testing
- Trastuzumab combined with Pyrotinib and chemotherapy
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Peking University
Breast Cancer Female
Young Patients With Early Breast Cancer
The prognosis of young patients with breast cancer is relatively poor. Chemotherapy damages ovarian function. Endocrine treatment for up to 10 years delays the childbearing time of patients.
- Trial name
- NCT06027541
- Testing
- operation
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Colon Cancer
EXoPERT EMERALD Clinical Study
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT07186296
- Testing
- EXoPred
- Where
- 9 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- EXoPERT
Breast Cancer, Surgery
Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery
to analyze the feasibility for patients with early luminal breast cancer to be compliant with a diet modification - ketogenic or proteins restricted diet - during 9 +/- 1 days, before breast cancer surgery.
- Trial name
- MACS (NCT04469296)
- Testing
- iso-caloric ketogenic diet, protein restricted diet
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast…
- Trial name
- NCT01194869
- Testing
- Sorafenib, Cisplatin, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Early-stage Breast Cancer, Diarrhea
Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer
The present study aims to investigate a proactive strategy including Salovum™ and SPC-flakes to prevent the occurrence of abemaciclib-induced diarrhea in patients with early breast cancer.
- Conditions
- Early-stage Breast Cancer, Diarrhea, Adverse Drug Event
- Trial name
- ASF-BC (NCT06152471)
- Testing
- SPC-flakes, Salovum
- Where
- 7 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Henrik Lindman
Breast Cancer
Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy
Radiotherapy plays an integral role in breast cancer therapy. Multiple randomized studies have demonstrated decreased local-regional recurrence rates and decreased breast-cancer mortality.
- Trial name
- NCT02496260
- Testing
- Research Cardiac MRI, Biomarkers
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Henry Ford Health System
Breast Cancer
Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. Diagnostic procedures, such as ductal lavage, may improve the ability to assess the effectiveness of…
- Trial name
- NCT00083044
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Breast Cancer, Surgery
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. However, Hypofractionation with simultaneous integrated boost has been investigating in breast cancer.
- Conditions
- Breast Cancer, Surgery, Adjuvant Radiotherapy
- Trial name
- NCT04913532
- Testing
- Hypofractionation with simultaneous integrated boost
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Capital Medical University
Breast Cancer, Early-stage Breast Cancer
SABER Study for Selected Early Stage Breast Cancer
The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.
- Trial name
- SABER (NCT04360330)
- Testing
- Stereotactic Ablative Breast Radiotherapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Miami